2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer

Laura Fugazzola, Rossella Elisei, Dagmar Fuhrer, Barbara Jarzab, Sophie Leboulleux, Kate Newbold, Jan Smit

Research output: Contribution to journalReview article

Abstract

The vast majority of thyroid cancers of follicular origin (TC) have a very favourable outcome, but 5-10% of cases will develop metastatic disease. Around 60-70% of this subset, hence less than 5% of all patients with TC, will become radioiodine refractory (RAI-R), with a significant negative impact on prognosis and a mean life expectancy of 3-5 years. Since no European expert consensus or guidance for this challenging condition is currently available, a task force of TC experts was nominated by the European Thyroid Association (ETA) to prepare this document based on the principles of clinical evidence. The task force started to work in September 2018 and after several revision rounds, prepared a list of recommendations to support the treatment and follow-up of patients with advanced TC. Criteria for advanced RAI-R TC were proposed, and the most appropriate diagnostic tools and the local, systemic and palliative treatments are described. Systemic therapy with multikinase inhibitors is fully discussed, including recommendations on how to start it and at which dosage, on the duration of treatment, and on the management of side effects. The appropriate relationship between the specialist and the patient/family as well as ethical issues are covered. Based on the available studies and on personal experience, the experts provided 39 recommendations aimed to improve the management of advanced RAI-R TCs. Above all of them is the indication to treat and follow these patients in a specialized setting which allows the interaction between several specialists in a multidisciplinary team.

Original languageEnglish
Pages (from-to)227-245
Number of pages19
JournalEuropean Thyroid Journal
Volume8
Issue number5
DOIs
Publication statusPublished - Oct 1 2019

Fingerprint

Thyroid Neoplasms
Guidelines
Advisory Committees
Therapeutics
Life Expectancy
Palliative Care
Ethics
Consensus

Keywords

  • Advanced thyroid cancer
  • European Thyroid Association
  • Familial counselling
  • Lenvatinib
  • Local treatments
  • Multikinase inhibitors
  • Radioiodine refractory thyroid cancer
  • Rehabilitation
  • Sorafenib

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer. / Fugazzola, Laura; Elisei, Rossella; Fuhrer, Dagmar; Jarzab, Barbara; Leboulleux, Sophie; Newbold, Kate; Smit, Jan.

In: European Thyroid Journal, Vol. 8, No. 5, 01.10.2019, p. 227-245.

Research output: Contribution to journalReview article

Fugazzola, L, Elisei, R, Fuhrer, D, Jarzab, B, Leboulleux, S, Newbold, K & Smit, J 2019, '2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer', European Thyroid Journal, vol. 8, no. 5, pp. 227-245. https://doi.org/10.1159/000502229
Fugazzola, Laura ; Elisei, Rossella ; Fuhrer, Dagmar ; Jarzab, Barbara ; Leboulleux, Sophie ; Newbold, Kate ; Smit, Jan. / 2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer. In: European Thyroid Journal. 2019 ; Vol. 8, No. 5. pp. 227-245.
@article{efb11130f3924fb286373e95b0a986fd,
title = "2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer",
abstract = "The vast majority of thyroid cancers of follicular origin (TC) have a very favourable outcome, but 5-10{\%} of cases will develop metastatic disease. Around 60-70{\%} of this subset, hence less than 5{\%} of all patients with TC, will become radioiodine refractory (RAI-R), with a significant negative impact on prognosis and a mean life expectancy of 3-5 years. Since no European expert consensus or guidance for this challenging condition is currently available, a task force of TC experts was nominated by the European Thyroid Association (ETA) to prepare this document based on the principles of clinical evidence. The task force started to work in September 2018 and after several revision rounds, prepared a list of recommendations to support the treatment and follow-up of patients with advanced TC. Criteria for advanced RAI-R TC were proposed, and the most appropriate diagnostic tools and the local, systemic and palliative treatments are described. Systemic therapy with multikinase inhibitors is fully discussed, including recommendations on how to start it and at which dosage, on the duration of treatment, and on the management of side effects. The appropriate relationship between the specialist and the patient/family as well as ethical issues are covered. Based on the available studies and on personal experience, the experts provided 39 recommendations aimed to improve the management of advanced RAI-R TCs. Above all of them is the indication to treat and follow these patients in a specialized setting which allows the interaction between several specialists in a multidisciplinary team.",
keywords = "Advanced thyroid cancer, European Thyroid Association, Familial counselling, Lenvatinib, Local treatments, Multikinase inhibitors, Radioiodine refractory thyroid cancer, Rehabilitation, Sorafenib",
author = "Laura Fugazzola and Rossella Elisei and Dagmar Fuhrer and Barbara Jarzab and Sophie Leboulleux and Kate Newbold and Jan Smit",
year = "2019",
month = "10",
day = "1",
doi = "10.1159/000502229",
language = "English",
volume = "8",
pages = "227--245",
journal = "European Thyroid Journal",
issn = "2235-0640",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - 2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer

AU - Fugazzola, Laura

AU - Elisei, Rossella

AU - Fuhrer, Dagmar

AU - Jarzab, Barbara

AU - Leboulleux, Sophie

AU - Newbold, Kate

AU - Smit, Jan

PY - 2019/10/1

Y1 - 2019/10/1

N2 - The vast majority of thyroid cancers of follicular origin (TC) have a very favourable outcome, but 5-10% of cases will develop metastatic disease. Around 60-70% of this subset, hence less than 5% of all patients with TC, will become radioiodine refractory (RAI-R), with a significant negative impact on prognosis and a mean life expectancy of 3-5 years. Since no European expert consensus or guidance for this challenging condition is currently available, a task force of TC experts was nominated by the European Thyroid Association (ETA) to prepare this document based on the principles of clinical evidence. The task force started to work in September 2018 and after several revision rounds, prepared a list of recommendations to support the treatment and follow-up of patients with advanced TC. Criteria for advanced RAI-R TC were proposed, and the most appropriate diagnostic tools and the local, systemic and palliative treatments are described. Systemic therapy with multikinase inhibitors is fully discussed, including recommendations on how to start it and at which dosage, on the duration of treatment, and on the management of side effects. The appropriate relationship between the specialist and the patient/family as well as ethical issues are covered. Based on the available studies and on personal experience, the experts provided 39 recommendations aimed to improve the management of advanced RAI-R TCs. Above all of them is the indication to treat and follow these patients in a specialized setting which allows the interaction between several specialists in a multidisciplinary team.

AB - The vast majority of thyroid cancers of follicular origin (TC) have a very favourable outcome, but 5-10% of cases will develop metastatic disease. Around 60-70% of this subset, hence less than 5% of all patients with TC, will become radioiodine refractory (RAI-R), with a significant negative impact on prognosis and a mean life expectancy of 3-5 years. Since no European expert consensus or guidance for this challenging condition is currently available, a task force of TC experts was nominated by the European Thyroid Association (ETA) to prepare this document based on the principles of clinical evidence. The task force started to work in September 2018 and after several revision rounds, prepared a list of recommendations to support the treatment and follow-up of patients with advanced TC. Criteria for advanced RAI-R TC were proposed, and the most appropriate diagnostic tools and the local, systemic and palliative treatments are described. Systemic therapy with multikinase inhibitors is fully discussed, including recommendations on how to start it and at which dosage, on the duration of treatment, and on the management of side effects. The appropriate relationship between the specialist and the patient/family as well as ethical issues are covered. Based on the available studies and on personal experience, the experts provided 39 recommendations aimed to improve the management of advanced RAI-R TCs. Above all of them is the indication to treat and follow these patients in a specialized setting which allows the interaction between several specialists in a multidisciplinary team.

KW - Advanced thyroid cancer

KW - European Thyroid Association

KW - Familial counselling

KW - Lenvatinib

KW - Local treatments

KW - Multikinase inhibitors

KW - Radioiodine refractory thyroid cancer

KW - Rehabilitation

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85071601779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071601779&partnerID=8YFLogxK

U2 - 10.1159/000502229

DO - 10.1159/000502229

M3 - Review article

AN - SCOPUS:85071601779

VL - 8

SP - 227

EP - 245

JO - European Thyroid Journal

JF - European Thyroid Journal

SN - 2235-0640

IS - 5

ER -